What is the FDA Approved Nrf2 Activator? A Comprehensive Overview
•
3 min read
In February 2023, the U.S. Food and Drug Administration (FDA) approved omaveloxolone (Skyclarys), the first and only Nrf2 activator specifically indicated for the treatment of Friedreich's ataxia. These specialized medications function by targeting the Nrf2 pathway to help the body combat oxidative stress and inflammation.
